Abbott Laboratories

Business description

Abbott Laboratories is a diversified health care products company operating across four segments: medical devices (48% of 2025 sales), diagnostics (20%), nutritional products (19%), and established pharmaceuticals (12%). The company holds leading market positions in diabetes care (Freestyle Libre CGM), cardiovascular devices, and noninvasive cancer screening following the Exact Sciences acquisition.

Key financials

• Price: USD 100.68 (07/17/2026)
• 12-Mo Target: USD 120.00
• Market Cap: USD 175.37B
• CFRA Rating: Buy
• H-Score: 77

Competitive moat

• Diversified health care portfolio spanning devices, diagnostics, nutrition, and generics insulates against single-market disruption.
• Strong brand equity in diabetes care (Freestyle Libre) with partnerships across five major insulin pump manufacturers.
• Leading position in noninvasive colorectal cancer screening via Cologuard / Cologuard Plus post-Exact Sciences acquisition.
• Sustained R&D investment ($2.94B in 2025) and a pipeline of 25+ innovative products expected over the next three years.
• Sturdy balance sheet with moderate leverage (20% debt/capital) and a 2.50% dividend yield with 54 years of consecutive payouts.

Recent developments

• Exact Sciences acquisition closed (March 2026): $21B equity value deal expands diagnostics TAM from $60B to $120B; Cologuard Plus provides runway in colorectal screening.
• Q2 2026 beat: Comparable sales growth of 4.8%, adjusted EPS of $1.31 exceeding guidance and consensus; full-year guidance raised.
• Strong product pipeline: Volt PFA system, TriClip enhancements, and Freestyle Libre 3 driving organic growth; 25 innovative products anticipated over three years.
• Nutrition recovery underway: Ongoing rebound in the nutrition business expected to support 2H 2026 momentum.

Investment risks / red flags

• Nutrition recovery execution: Dependent on continued market share recapture and sustained infant formula production stability following 2022 recall disruptions.
• China VBP exposure: Volume-Based Purchasing continues to pressure Diagnostics segment; could expand to other markets.
• GLP-1 medication impact: Growth in GLP-1 usage may affect procedure volumes and consumables demand.
• Regulatory timing: U.S. reimbursement expansion for CGM in Type 2 non-insulin patients remains an unpredictable catalyst.

H-Score signals

• TBI multi factor score: 77
• Balanced score reflecting solid value and momentum in a diversified health care leader.

Theme exposure

• [[health-care-equipment]]
• [[diagnostics]]

Related

• [[Health Care Equipment]]
• [[Edwards Lifesciences Corporation]]